Stockscreener 앱 받기
4.59
1.92%
-0.09
시간 외 거래:
4.59
전일 마감가:
$4.68
열려 있는:
$4.71
하루 거래량:
860.96K
Relative Volume:
1.10
시가총액:
$190.01M
수익:
$134.48M
순이익/손실:
$-38.94M
주가수익비율:
-4.8143
EPS:
-0.9534
순현금흐름:
$-19.34M
1주 성능:
-0.22%
1개월 성능:
-19.19%
6개월 성능:
-63.57%
1년 성능:
-66.00%
1일 변동 폭
$4.56
$4.83
1주일 범위
$4.48
$4.94
52주 변동 폭
$4.48
$14.29
Rxsight Inc Stock (RXST) Company Profile
명칭
Rxsight Inc
전화
949-521-7822
주소
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
4.59 | 198.29M | 134.48M | -38.94M | -19.34M | -0.9534 |
ABT
Abbott Laboratories
|
88.50 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.14 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.14 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.95 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.68 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 개시 | William Blair | Mkt Perform |
| 2025-07-15 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-07-09 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-07-09 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-07-09 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | 개시 | Piper Sandler | Neutral |
| 2025-04-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-04-04 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2025-04-03 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-12-20 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | 개시 | UBS | Buy |
| 2024-10-29 | 개시 | Jefferies | Buy |
| 2024-08-20 | 재확인 | Needham | Buy |
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-05-07 | 재확인 | BTIG Research | Buy |
| 2023-12-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | 개시 | Stifel | Buy |
| 2023-12-04 | 개시 | Morgan Stanley | Overweight |
| 2023-04-13 | 개시 | Oppenheimer | Outperform |
| 2022-12-12 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | 개시 | Needham | Buy |
모두보기
Rxsight Inc 주식(RXST)의 최신 뉴스
RxSight, Inc. Hits 52-Week Low of $4.58 Amidst 92.2% Decline - MarketsMojo
RxSight, Inc. Stock Plummets to New 52-Week Low of $4.49 - Markets Mojo
RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates - MSN
RxSight Inc. (RXST) Falters Near Support: Testing Key Levels After 1.96% DeclineDark Pool Sentiment - newsline.com
Understanding Momentum Shifts in (RXST) - Stock Traders Daily
RxSight, Inc. Hits 52-Week Low at $5.31 Amid Ongoing Struggles - MarketsMojo
RxSight, Inc. Hits 52-Week Low at USD 4.93 Amidst Ongoing Struggles - MarketsMojo
RxSight Inc. (RXST) Slides 3% as Stock Struggles Below Key Resistance at $5.03Hedge Fund Exposure - newsline.com
RxSight Inc. (RXST) Q1 2026 Earnings: EPS Miss Weighs on Shares Amid Operating ChallengesProfitability Analysis - newsline.com
RXST Technical Analysis & Stock Price Forecast - Intellectia AI
RxSight Inc stock (US78419L1008): Nasdaq-listed eye-care specialist in focus after recent price weak - AD HOC NEWS
RXST Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin; Stock DeclinesEarnings Call Highlights - newsline.com
RxSight Inc. (RXST) Slips 4.65% as Stock Challenges $5.06 Support LevelTICK Divergence - The Legal Advocate
RxSight Securities Lawsuit Advances After Court Denies Dismissal Bid - TipRanks
RXST Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing Ramp-UpEPS Growth Rate - The Legal Advocate
Midday Stock Roundup: TTM Drops on Investor Day - Orange County Business Journal
RxSight Must Litigate Investor Suit Over Eye Lens System Demand - Bloomberg Law News
RXST: Premium IOL penetration grows as competitive headwinds ease and commercial focus intensifies - TradingView
Avoiding Lag: Real-Time Signals in (RXST) Movement - Stock Traders Daily
RxSight Inc. Q1 2026 Earnings: EPS Misses Estimates Amid Operational HeadwindsOne-Time Loss Impact - Newser
RxSight Q1 2026 Earnings: EPS Misses Estimates by 32% as Operational Costs WeighEarnings Beat Streak - The Legal Advocate
RxSight stock gains ahead of Stifel meeting, investors wait for signs of turnaround - Bez Kabli
RxSight to present at Stifel 2026 Virtual Ophthalmology Forum on May 26 - Pluang
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum - The Manila Times
RxSight stock (US78419L1008): Q1 revenue dip and share slide put growth story to the test - AD HOC NEWS
Tarsus, RxSight Fall Despite Growth Signals - Orange County Business Journal
RxSight stock (US78419L1008): FDA-linked growth and execution stay in focus - AD HOC NEWS
RxSight stock (US78419L1008): FDA-backed growth story stays in focus - AD HOC NEWS
Number of shareholders of RxSight, Inc. – NASDAQ:RXST - TradingView
Discipline and Rules-Based Execution in RXST Response - Stock Traders Daily
RxSight Earnings Call Balances Growth With Headwinds - TipRanks
TradingKey - TradingKey
BofA Securities Maintains RxSight(RXST.US) With Sell Rating - Moomoo
RXST: Stable Q1 results and ongoing commercial initiatives support sequential growth and global expansion - TradingView
Artisan Partners reports 5.0% stake in RxSight (NASDAQ: RXST) - Stock Titan
Midday Stock Roundup: Skyworks Solutions Falls - Orange County Business Journal
RxSight (RXST) Q1 2026 Earnings Transcript - AOL.com
RxSight, Inc. (NASDAQ:RXST) Q1 2026 Earnings Call Transcript - Insider Monkey
RxSight (RXST) Gets a Hold from Stifel Nicolaus - The Globe and Mail
William Blair Maintains RxSight(RXST.US) With Hold Rating - Moomoo
RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook - VisionMonday.com
Piper Sandler Maintains RxSight(RXST.US) With Hold Rating, Maintains Target Price $10 - Moomoo
RxSight, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Rxsight Inc (RXST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rxsight Inc 주식 (RXST) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Goldshleger Ilya | See remarks |
Sep 25 '25 |
Option Exercise |
4.27 |
23,445 |
99,998 |
65,691 |
2.43%
자본화:
|
볼륨(24시간):